Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit

Neurosurgery

Volumn 41, Issue 6, 1997, Pages 1385-1392

  Arthur, Adam S ^a   Fergus, Allan H ^a   Lanzino, Giuseppe ^a   Mathys, Jeff ^a   Kassell, Neal F ^a   Lee, Kevin S ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cerebral vasospasm; Deferiprone; L1; Oxygen free radical; Rabbit; Subarachnoid hemorrhage

Indexed keywords

DEFERIPRONE; FREE RADICAL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN VASOSPASM; CATALYSIS; DISEASE ASSOCIATION; IRON CHELATION; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPECIES DIFFERENTIATION; SUBARACHNOID HEMORRHAGE; TREATMENT PLANNING;

EID: 0030780828     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199712000-00028     Document Type: Article

References (40)

1. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT: Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassemia: Indian trial. Br J Haematol 82:460-466, 1992.
2. Al Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ: Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 80:593-599, 1992.
3. Asano T, Tanishima T, Sasaki T: Possible participation of free radical reactions initiated by clot lysis in the pathogenesis of vasospasm after subarachnoid hemorrhage, in Wilkins RH (ed): Cerebral Arterial Spasm. Baltimore, Williams & Wilkins, 1980, pp 190-201.
4. Berdoukas V, Bentley P, Frost H, Schnebli HP: Toxicity of oral iron chelator L1. Lancet 341:1088, 1993 (letter).
5. Comair YG, Schipper HM, Brem S: The prevention of oxyhemoglobin-induced endothelial and smooth muscle cytoskeletal injury by deferoxamine. Neurosurgery 32:58-65, 1993.
6. Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G: Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous β-thalassemia. Clin Pharmacol Ther 55: 70-75, 1994.
7. Fredenburg AM, Sethi RK, Allen DD, Yokel RA: The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 108:191-199, 1996.
8. Gale GR, Lichtenberg WH, Smith AB, Singh PK, Campbell RA, Jones MM: Comparative iron mobilizing actions of deferoxamine, 1,2-dimethvl-3-hydroxypyrid-4-one, and pyridoxal isonicotinoyl hydrazone in iron hydroxamate-loaded mice. Res Commun Chem Pathol Pharmacol 73:299-313, 1991.
9. Haley EC Jr, Kassell NF, Alves WM, Weir BK, Hansen CA: Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage: A report of the Cooperative Aneurysm Study. J Neurosurg 82:786-790, 1995.
10. Halliwell B, Gutteridge JMC: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochemistry 219:1-14, 1984.
11. Hamilton KO, Stallibrass L, Hassan I, Jin Y, Halleux C, Mackay M: The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers. Br J Haematol 86:851-857, 1994.
12. Harada T, Mayberg MR: Inhibition of delayed arterial narrowing by the iron-chelating agent deferoxamine. J Neurosurg 77:763-767, 1992.
13. Hider RC, Kontoghiorghes GJ, Silver J: U.K. Patent GB-2118176, 1982.
14. Hoyes KP, Porter JB: Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 83:393-400, 1993.
15. Kamiyama K, Okada H, Suzuki J: The relation between cerebral vasospasms and superoxide: Application of an experimental model of vasospasms induced by oxyhemoglobin in cats. Neurol Med Chir (Tokyo) 21:201-209, 1981.
16. Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL: The international cooperative study on the timing of aneurysm surgery: Part 1 - Overall management results. J Neurosurg 73:18-36, 1990.
17. Komara JS, Nayini NR, Bialick HA, Indrieri RJ, Evans AT, Garritano AM, Hoehner TS, Jacobs WA, Huang RR, Krause GS: Brain iron delocalization and lipid peroxidation following cardiac arrest. Ann Emerg Med 15:384-389, 1986.
18. Kontoghiorghes GJ: Design, properties, and effective use of the oral chelator L1 and other α-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia. Ann N Y Acad Sci 34:339-350, 1992.
19. Kontoghiorghes GJ: Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J Pediatr 60:485-507, 1993.
20. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L: Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 48:255-261, 1990.
21. Kontoghiorghes GJ, Hoffbrand AV: Orally active α-ketohydroxypyridine iron chelators intended for clinical use: In vivo studies in rabbits. Br J Haematol 62:607-613, 1986.
22. Luo Z, Harada T, London S, Gajdusek C, Mayberg MR: Antioxidant and iron-chelating agents in cerebral vasospasm. Neurosurgery 37:1154-1159, 1995.
23. Macdonald RL, Weir BKA, Runzer TD, Grace MG, Findlay JM, Saito K, Cook DA, Mielke BW, Kanamaru K: Etiology of cerebral vasospasm in primates. J Neurosurg 75:415-424, 1991.
24. Meerson FZ, Kagan VE, Koloz YP, Belkina LM, Arkhipenko YV: The role of lipid peroxidation in the pathogenesis of ischemia damage and the antioxidant protection of the heart. Basic Res Cardiol 77:465-485, 1982.
25. Misra HP, Fridovich I: The generation of superoxide radical during the autoxidation of hemoglobin. J Biol Chem 247:6960-6962, 1972.
26. Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P: Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: Comparison of their mechanism of protection with that of desferrioxamine. Free Radic Biol Med 13:499-508, 1992.
27. Nakagomi T, Kassell NF, Hongo K, Sasaki T: Pharmacological reversibility of experimental cerebral vasospasm. Neurosurgery 27:582-586, 1990.
28. Okamoto S, Handa H, Toda N: Role of intrinsic arachidonate metabolites in the vascular action of erythrocyte breakdown products. Stroke 15:60-64, 1984.
29. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM: Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 79:2741-2748, 1992.
30. Reuter DG, Tacker WA Jr, Babbs CF, Badylak SF, Voorhees WE III, Konrad PE: Preliminary results of deferoxamine and L1 treatment of spinal cord ischemia. J Thorac Cardiovasc Surg 109:1017-1019, 1995.
31. Sano K, Asano T, Tanishima T, Sasaki T: Lipid peroxidation as a cause of cerebral vasospasm. Neurol Res 2:253-272, 1980.
32. Sasaki T, Tanishima T, Asano T, Mayanagi Y, Sano K: Significance of lipid peroxidation in the genesis of chronic vasospasm following rupture of an intracranial aneurysm. Acta Neurochir Suppl (Wien) 28:536-540, 1979.
33. Sasaki T, Wakai S, Asano T, Watanabe T, Kirino T, Sano K: The effect of a lipid hydroperoxide of arachidonic acid on the canine basilar artery: An experimental study on cerebral vasospasm. J Neurosurg 54:357-365, 1981.
34. Steele JA, Stockbridge N, Malijkovic G, Weir B: Free radicals mediate actions of oxyhemoglobin on cerebrovascular smooth muscle cells. Circ Res 68:416-423, 1991.
35. Takahashi S, Kassell NF, Toshima M, Dougherty DA, Foley PL, Lee KS: Effect of U88999E on experimental cerebral vasospasm in rabbits. Neurosurgery 32:281-288, 1993.
36. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sunderegger T, Wagner HP: L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelarion in patients with beta-thalassaemia major. Br J Haematol 76:550-553, 1990.
37. Traystman RJ, Kirsch JR, Koehler RC: Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 71:1185-1195, 1991.
38. Vollmer DG, Hongo K, Ogawa H, Tsukahara T, Kassell NF: A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. Neurosurgery 28:27-32, 1991.
39. Vollrath B, Chan P, Findlay M, Cook D: Lazaroids and deferoxamine attenuate the intracellular effects of oxyhaemoglobin in vascular smooth muscle. Cardiovasc Res 30:619-626, 1995.
40. Wellum GR, Irvine TW Jr, Zervas NT: Cerebral vasoactivity of heme proteins in vitro: Some mechanistic considerations. J Neurosurg 56:777-783, 1982.